February 8, 2005 -- Pfizer Inc. reported that its experimental kinase inhibitor drug, SU11248, proved safe and effective in a late-stage trial for gastro-intestinal stromal tumors (GIST). The trial was ended 7 months ahead of schedule due to unexpectedly good results. Patients on placebo now have the option of switching to the drug. We look at the drug, further indications for which it may be approved, and what it says about Pfizer...
